Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: a conceivable alternative?

PubWeight™: 0.86‹?›

🔗 View Article (PMID 9422472)

Published in Bone Marrow Transplant on December 01, 1997

Authors

A Borgmann1, E Baumgarten, H Schmid, R Dopfer, W Ebell, U Göbel, D Niethammer, H Gadner, G Henze

Author Affiliations

1: Department of Paediatric Haematology and Oncology of the Virchow Medical Center, Berlin, Germany.

Articles by these authors

Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol (2000) 4.15

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91

Mycoplasma pneumoniae adhesin localized to tip structure by monoclonal antibody. Nature (1982) 3.89

Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83

Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene (1990) 3.74

X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med (1998) 3.45

Concurrent Langerhans cell histiocytosis and myelodysplasia in children. Med Pediatr Oncol (2000) 3.24

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia (2008) 3.23

Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood (2000) 3.13

Patterned delivery of immunoglobulins to surfaces using microfluidic networks. Science (1997) 2.79

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78

HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol (1997) 2.59

Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood (1999) 2.48

Oral vitamin K prophylaxis and late haemorrhagic disease of the newborn. Lancet (1994) 2.35

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30

Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol (1999) 2.25

Chicken NFI/TGGCA proteins are encoded by at least three independent genes: NFI-A, NFI-B and NFI-C with homologues in mammalian genomes. Nucleic Acids Res (1990) 2.24

Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood (2000) 2.21

Compartment specific expression of dendritic cell markers in human glomerulonephritis. Kidney Int (2008) 2.21

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia (2000) 2.21

MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer (1991) 2.15

Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11

Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer (1988) 2.11

Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med (1996) 2.05

Progress in chimerism analysis in childhood malignancies--the dilemma of biostatistical considerations and ethical implications. Leukemia (2001) 2.02

Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol (2001) 2.01

In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood (1995) 2.00

Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed (1997) 1.99

Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood (2000) 1.93

Malignant peripheral neuroectodermal tumors. A retrospective analysis of 42 patients. Cancer (1988) 1.92

Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum (1998) 1.86

Filamentous structures in adherent Mycoplasma pneumoniae cells treated with nonionic detergents. J Cell Biol (1981) 1.79

Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood (1999) 1.75

Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res (2001) 1.75

Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol (1995) 1.72

Occurrence of acute nonlymphoblastic leukemia in two girls after treatment of recurrent, disseminated Langerhans cell histiocytosis. Pediatr Hematol Oncol (1999) 1.67

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia (2001) 1.67

Ovarian sex cord-stromal tumors in children and adolescents. J Clin Oncol (2003) 1.66

Inhibition of 3H-thymidine incorporation of lymphocytes by a soluble factor from macrophages. Cell Immunol (1975) 1.65

HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis (2006) 1.64

Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64

Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature. Hum Pathol (2003) 1.64

Evidence for at least eight Fanconi anemia genes. Am J Hum Genet (1997) 1.61

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia (2005) 1.60

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer (1995) 1.59

Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol (1993) 1.57

Validation of the German version of the Pediatric Quality of Life Inventory (PedsQL) in childhood cancer patients off treatment and children with epilepsy. Qual Life Res (2004) 1.56

Cell-autonomous and inductive signals can determine the sex of the germ line of drosophila by regulating the gene Sxl. Cell (1989) 1.55

Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood (2001) 1.55

Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol (1993) 1.52

Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood (1991) 1.52

Impact of whole-body MRI and FDG-PET on staging and assessment of therapy response in a patient with Ewing sarcoma. Pediatr Blood Cancer (2006) 1.51

Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant (2001) 1.50

Vitamin K in infancy. Eur J Pediatr (1988) 1.49

Lack of DNA synthesis among CD34+ cells in cord blood and in cytokine-mobilized blood. Br J Haematol (1996) 1.48

Correction of persistent thrombocytopenia by a boost of CD133+ selected stem cells in a patient transplanted for Wiskott-Aldrich syndrome 10 years ago. Bone Marrow Transplant (2004) 1.48

Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood (2000) 1.47

Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age. Pediatr Hematol Oncol (1998) 1.46

Vertebra plana due to a Ewing tumor. Med Pediatr Oncol (1999) 1.45

Natural course of a Wilms' tumour. Lancet (1999) 1.45

Oncological management of pediatric cancer patients belonging to Jehovah's Witnesses: a two-institutional experience report. Onkologie (2004) 1.44

Biochemical characterization of a factor released by macrophages. Cell Immunol (1975) 1.44

A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother (1992) 1.44

Pneumococcal arthritis after allogeneic bone marrow transplantation. Bone Marrow Transplant (1993) 1.43

Autologous bone-marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. The Berlin-Frankfurt-Münster Study Group. Lancet (1995) 1.42

Multipoint imprinting analysis indicates a common precursor cell for gonadal and nongonadal pediatric germ cell tumors. Cancer Res (2001) 1.42

Fosfomycin does not reduce cytostatic activity of cis-platinum against human osteosarcoma cell lines in vitro. Pediatr Hematol Oncol (1992) 1.41

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol (1998) 1.41

Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer (2006) 1.41

EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ (1996) 1.40

Teratomas in infancy and childhood. Med Pediatr Oncol (1998) 1.40

Low-grade non-Hodgkin's lymphoma after high-grade non-Hodgkin's lymphoma in a child with ataxia telangiectasia. Cancer (1994) 1.40

TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Berlin-Frankfurt-Münster Study Group. Leukemia (1999) 1.40

Basic methods and the developing structure of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. For the German Late Effects Study Group in the German Society Pediatric Oncology and Hematology (GPOH). Med Pediatr Oncol (2000) 1.40

New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. Klin Wochenschr (1979) 1.39

Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state. Blut (1990) 1.39

Diagnostic and therapeutic pitfalls in infants with large sacrococcygeal tumors. Pediatr Hematol Oncol (1999) 1.39

Renal anaemia of an unusual origin. Nephrol Dial Transplant (2001) 1.38

Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene (1993) 1.37

Heterogeneous spectrum of mutations in the Fanconi anaemia group A gene. Eur J Hum Genet (1999) 1.36

Isolation of atypical mycobacteria from tap water in hospitals and homes: is this a possible source of disseminated MAC infection in AIDS patients? J Infect (1995) 1.36